Claudin 6: High Anti-Tumour Activity Seen in Clinical Trials
- Friday, July 22, 2022, 7:04
- Finance
- Add a comment
DUBLIN, July 22, 2022 /PRNewswire/ — The “Claudin 6: A Target Opportunity To Develop Effector-Enhanced Drug Modalities” report has been added to ResearchAndMarkets.com’s offering. Claudin 6 (CLDN6) is a compelling tumor antigen. The tetraspan membrane protein is a member of the claudin…
About the Author
adminasapcorp has written 41555 stories on this site.